再融2.5亿！创新消融企业完成B轮

Core Viewpoint - Field Medical has successfully completed a $35 million Series B financing round, bringing its total funding to $75 million, aimed at advancing its FieldForce™ ablation system and initiating the VERITAS clinical trial for treating complex arrhythmias, particularly ventricular tachycardia (VT) [1][4][6]. Financing Details - Field Medical, founded in 2022 by Steven Mickelsen, focuses on developing pulse field ablation (PFA) technology for arrhythmia treatment, with its core product being the FieldForce™ ablation system [2][6]. - The Series B financing was led by BioStar Capital and Cue Growth, with participation from existing strategic investors, to support the development of the FieldForce™ system and the upcoming VERITAS clinical trial [4][6]. Clinical Trials and Research - The VERITAS clinical trial is a pivotal study designed to validate the safety and efficacy of the FieldForce™ system in treating complex arrhythmias, marking a significant step towards clinical validation [4][6]. - Field Medical has initiated its first human study, the Ventricular Catheter Ablation Study (VCAS), in May 2024, aiming to demonstrate the safety and performance of its PFA system [17][18]. Technology Overview - The FieldForce™ system utilizes innovative PFA technology designed specifically for the ventricles, aiming to provide a safer and more effective treatment option for ventricular tachycardia [10][16]. - The FieldBending technology enhances the PFA catheter's performance by improving contact force with the tissue, which is crucial for effective treatment [11][16]. Market Potential - The VT market is characterized by high clinical demand and a lack of adequate treatment tools, similar to the early stages of the atrial fibrillation market, presenting a significant opportunity for Field Medical [7][8]. - Initial data from the FieldForce system shows promising potential to transform traditional catheter ablation procedures for complex ventricular arrhythmias, possibly exceeding current care standards [22].